antivir
monoclon
antibodi
mab
repres
promis
therapeut
howev
mabsbas
immunotherapi
conduct
far
consid
blunt
viral
propag
possibl
therapeut
effect
independ
viru
neutral
name
modul
endogen
immun
respons
induct
longterm
antivir
immun
still
remain
paramount
challeng
treat
chronic
infect
ask
whether
neutral
mab
addit
blunt
viral
propag
exert
immunomodulatori
effect
protect
outcom
support
idea
report
mice
infect
frca
e
murin
retroviru
day
birth
die
leukemia
within
month
mount
nonprotect
immun
respons
wherea
rapidli
subject
short
immunotherapi
neutral
mab
surviv
healthi
mount
longlast
protect
antivir
immun
strong
humor
cellular
immun
respons
interestingli
administ
mab
mediat
lysi
infect
cell
antibodydepend
cell
cytotox
adcc
mechan
addit
form
immun
complex
ic
infect
cell
enhanc
antivir
ctl
respons
fccrmediat
bind
dendrit
cell
dc
importantli
endogen
antivir
antibodi
gener
mabtreat
mice
also
display
properti
allow
contain
viral
propag
enhanc
memori
cellular
respons
disappear
administ
mab
thu
data
demonstr
neutral
antivir
mab
act
immunomodulatori
agent
capabl
stimul
protect
immun
last
long
end
treatment
also
show
import
role
infectedcellsantibodi
complex
induct
mainten
protect
immun
enhanc
primari
memori
antivir
tcell
respons
also
indic
target
infect
cell
virus
antibodi
crucial
elicit
effici
longlast
antivir
tcell
respons
must
consid
design
antivir
mabbas
immunotherapi
monoclon
antibodi
mab
constitut
largest
class
biomed
protein
increasingli
consid
therapeut
agent
fight
acut
chronic
sever
human
viral
diseas
mani
develop
recent
period
non
exclus
one
cite
neutral
mab
ebola
west
nile
wnv
cytomegalo
cmv
avian
human
influenza
sever
acut
respiratori
syndrom
sar
respiratori
syncyti
rsv
hepat
b
hbv
hepat
c
hcv
human
immunodefici
viru
hiv
shown
antivir
activ
preclin
studi
one
pavilizumab
direct
rsv
commerci
avail
wherea
other
see
inform
refer
current
test
clinic
studi
treat
either
acut
cytopath
infect
wnv
cmv
sever
chronic
infect
hbv
hcv
hiv
figur
amongst
heaviest
health
burden
worldwid
antivir
mabbas
treatment
conduct
far
whether
human
anim
model
consid
blunt
viral
propag
direct
viru
neutral
howev
mab
might
also
oper
via
complementari
mechan
owe
abil
interact
variou
compon
immun
system
via
effector
function
born
constant
region
exampl
certain
viral
antigen
express
surfac
infect
cell
envelop
glycoprotein
env
immunodeficiencyinduc
virus
like
hiv
cancerinduc
virus
like
hcv
murin
oncoretrovirus
may
also
permit
mab
target
viru
reservoir
via
complementdepend
cdc
antibodydepend
cell
cytotox
adcc
mediat
natur
killer
cell
moreov
mab
form
immun
complex
ic
viral
antigen
expos
surfac
virion
well
infect
cell
certain
virus
uptak
process
mhc
present
antigen
antigenpres
cell
apc
significantli
differ
depend
whether
complex
antibodi
may
ultim
impact
endogen
immun
sever
reason
altern
mode
action
mab
poorli
investig
vivo
date
first
technic
reason
antivir
activ
certain
mab
test
immunodefici
preclin
anim
model
second
certain
antivir
mab
origin
one
speci
test
preclin
model
speci
constant
regiondepend
antibodi
function
poorli
preserv
third
addit
pauciti
antivir
mab
clinic
trial
technic
ethic
limit
prevent
certain
investig
human
be
establish
whether
mabbas
treatment
orient
antivir
immun
respons
toward
longterm
protect
immun
last
long
mab
disappear
howev
import
might
influenc
design
mab
immunotherapi
sever
chronic
lifethreaten
viral
infect
address
issu
resort
infect
immunocompet
mice
frca
e
retroviru
one
rare
model
system
permit
extens
analysi
endogen
immun
respons
passiv
mabbas
immunotherapi
condit
chronic
infect
patholog
develop
frca
e
ecotrop
retroviru
deriv
friend
murin
leukemia
viru
mulv
upon
inocul
newborn
mice
age
day
first
propag
lymphoid
organ
penetr
central
nervou
system
cn
lead
fatal
neurodegener
within
month
contrast
anim
infect
later
stage
develop
neurolog
ill
due
inabl
frca
e
penetr
cn
day
birth
instead
may
develop
fatal
erythroleukemia
see
recent
shown
infect
newborn
mice
day
birth
briefli
treat
neutral
mab
shortli
infect
anim
surviv
show
sign
neurodegener
leukemia
year
surviv
good
health
due
exclus
immedi
effect
viral
load
prevent
brain
infect
also
depend
develop
endogen
longterm
protect
antivir
immun
contain
residu
viral
replic
clearanc
permit
mice
resist
viral
challeng
immun
typic
respons
compris
strong
cytotox
tcell
respons
frca
e
infect
cell
potent
antifrca
e
humor
respons
princip
made
moreov
rapidli
mount
mab
treatment
contrast
nonprotect
respons
usual
develop
mulvinfect
mice
eventu
die
virallyinduc
diseas
work
observ
import
suggest
case
suspicion
infect
lifethreaten
virus
hiv
hcv
rapid
administr
mabbas
immunotherapi
natur
antivir
respons
initi
may
favor
mount
potent
protect
immun
consid
strong
neutral
antibodi
respons
earli
phase
infect
usual
correl
better
longterm
control
variou
persist
virus
howev
small
fraction
infect
individu
develop
respons
persist
virus
induc
delay
weak
viru
neutral
antibodi
respons
correl
establish
chronic
infect
take
account
crucial
understand
endogen
protect
antivir
respons
gener
mabtreat
anim
long
last
whether
administ
mab
actual
exert
immunomodulatori
action
address
issu
frca
e
system
requir
detail
comparison
antivir
immun
respons
develop
nontreat
infect
mice
possibl
origin
acut
neonat
infect
model
simpli
infect
mice
mount
endogen
immun
respons
due
rapid
health
deterior
unpublish
data
therefor
develop
chronic
infect
set
use
older
mice
lead
death
anim
erythroleukemia
within
month
provid
suffici
time
inform
comparison
two
type
immun
respons
data
clearli
point
immunomodulatori
effect
administ
mab
moreov
reveal
import
mechan
wherebi
antivir
immun
initi
maintain
longterm
via
format
immun
complex
infect
cell
studi
consequ
design
futur
antivir
immunotherapi
transient
mab
treatment
effici
limit
viral
propag
prevent
mice
develop
frca
einduc
erythroleukemia
first
creat
model
chronic
infect
frca
e
lead
death
mice
erythroleukemia
clear
synchron
symptomatolog
achiev
viru
inocul
day
birth
mice
show
first
symptom
erythroleukemia
month
postinfect
spleen
swell
due
exacerb
erythroblast
prolifer
reduct
hematocrit
result
combin
blockad
erythropoiesi
infect
erythroblast
exhaust
noninfect
red
blood
cell
mice
usual
die
day
low
hematocrit
versu
control
anim
dramat
enlarg
spleen
increas
monoclon
antibodi
mab
constitut
largest
class
biotherapeut
protein
increasingli
consid
drug
fight
acut
chronic
sever
human
viral
diseas
antivir
mabbas
treatment
conduct
far
whether
human
anim
model
consid
blunt
viral
propag
direct
viru
neutral
howev
mab
might
also
oper
via
complementari
mechan
owe
abil
interact
variou
compon
immun
system
use
lethal
mous
model
retrovirallyinduc
leukemia
report
neutral
mab
administ
infect
mice
short
period
time
addit
direct
effect
viral
spread
induc
strong
longlast
antivir
immun
respons
protect
mice
diseas
develop
long
end
treatment
although
initi
mainten
longterm
immun
multifactori
demonstr
crucial
role
immun
complex
form
antivir
antibodi
infect
cell
process
work
reveal
thu
far
underappreci
vaccinelik
effect
antivir
neutral
mab
consid
futur
treatment
lifethreaten
viral
infect
weight
show
short
mab
treatment
prevent
infect
anim
develop
erythroleukemia
compar
frca
e
infect
mabtreat
infectedtr
mice
control
group
infect
mice
treat
infectednontr
ii
infect
mice
treat
isotypematch
control
mab
mab
infectedcontrol
mabtreat
mice
iii
noninfect
mice
receiv
noninfectedtr
administ
time
hour
viru
inocul
time
suffici
establish
infect
see
ref
day
later
infectedtr
mice
importantli
condit
becam
undetect
within
less
day
postinject
noninfectedtr
mice
infect
treat
mice
surviv
without
patholog
symptom
month
experi
wherea
infectednontreatedand
infectedcontrol
mabtreat
mice
die
erythroleukemia
month
postinfect
figur
final
spleen
major
organ
mulv
replic
assess
extent
could
affect
viral
propag
assay
serum
viremia
figur
number
infect
splenocyt
spleen
infecti
center
sic
figur
infectednontr
anim
viremia
transient
peak
focusform
unitsor
ffuml
day
postinfect
level
alreadi
high
day
postinfect
return
undetect
level
day
limit
detect
ffuml
infectedtr
anim
peak
reduc
approxim
narrow
viremia
undetect
day
postinfect
return
undetect
level
earlier
day
effect
mark
sic
viremia
infectednontr
mice
show
high
constant
level
sic
death
experi
termin
day
wherea
sic
reduc
earliest
time
point
test
onward
becam
undetect
day
limit
detect
sic
per
splenocyt
infectedtr
anim
importantli
signific
rebound
viral
propag
assay
sic
observ
infectedtr
mice
day
postinfect
suggest
exist
indirect
mechan
induc
mab
treatment
reductionelimin
retrovirusproduc
cell
clear
infectedtr
mice
infectedtr
mice
mount
stronger
humor
ctl
antifrca
e
immun
respons
infectednontr
mice
next
show
infectedtr
mice
develop
stronger
igg
respons
infectednontr
one
figur
experi
infectednontr
anim
display
stabl
rel
weak
mgml
antifrca
e
total
igg
level
death
sacrific
sever
leukem
anim
contrast
antivir
igg
accumul
much
higher
level
infectedtr
mice
peak
mgml
day
postinfect
still
high
level
mgml
end
experi
day
postinfect
although
antifrca
e
found
group
anim
alway
least
abund
predomin
increas
time
infectedtr
anim
figur
suggest
promin
tcell
respons
also
see
final
observ
frca
e
neutral
antibodi
titer
higher
infectedtr
mice
infect
nontreat
one
indic
neutral
activ
two
group
anim
roughli
proport
amount
antifrca
e
antibodi
figur
compar
cellular
immun
respons
frca
e
infect
cell
develop
infectednontr
infectedtr
anim
end
first
assess
primari
tcell
respons
frca
e
infect
cell
first
month
postinfect
flow
cytometri
analysi
splenic
lymphocyt
use
mhc
class
mhc
b
tetram
load
gagl
peptid
b
gagl
tetram
gagl
immunodomin
b
restrict
epitop
conserv
among
differ
mulv
strain
deriv
leader
region
glycosyl
transmembran
form
gag
precursor
polyprotein
gag
importantli
gag
express
infect
cell
incorpor
virion
infectednontr
infectedtr
mice
develop
transient
primari
tcell
respons
alreadi
detect
day
postinfect
peak
day
figur
howev
higher
latter
group
mice
peak
respons
also
consist
time
sic
reduct
mice
figur
infectednontr
anim
tcell
respons
drop
background
level
day
postinfect
figur
wherea
still
detect
infectedtr
mice
least
day
evidenc
quantif
b
gagl
tetram
cell
figur
also
analyz
phenotyp
gagl
peptidespecif
tcell
popul
remain
contract
phase
day
postinfect
b
gagl
tetram
cell
infectedtr
mice
hi
mean
wherea
cell
noninfect
mice
display
phenotyp
figur
moreov
major
hi
cell
lo
figur
interestingli
assess
express
reveal
b
gagl
tetram
cell
lo
hi
figur
figur
final
b
gagl
tetram
cell
demonstr
effector
function
reveal
product
ifnc
figur
taken
togeth
result
show
infectedtr
mice
gener
import
cell
memori
pool
mainli
compris
effectormemori
cell
assess
abil
gaglspecif
memori
cell
infectedtr
mice
trigger
effici
secondari
respons
experi
anim
challeng
frca
e
infect
splenocyt
day
postinfect
infectednontr
infectedtr
mice
analyz
day
later
expans
kill
activ
cell
pool
signific
memori
respons
found
infectednontr
anim
figur
although
presenc
weak
antivir
tcell
respons
sensit
assay
could
formal
exclud
see
contrast
robust
respons
detect
infect
treat
mice
time
point
test
figur
compar
respons
observ
challeng
frca
e
infect
cell
figur
moreov
strong
vivo
cytolyt
activ
direct
splenocyt
load
gagl
peptid
observ
infectedtr
mice
importantli
infectednontr
mice
show
weak
detect
cytolyt
activ
show
basal
cytolyt
activ
similar
found
control
noninfectednontr
anim
figur
thu
memori
cell
infectedtr
mice
develop
function
secondari
respons
lastli
found
infectedtr
mice
maintain
function
antifrca
e
cellular
respons
longterm
challeng
experi
conduct
month
postinfect
infectedtr
mice
nine
mice
normal
hematocrit
sign
splenomegali
durat
experi
wherea
one
mous
show
clinic
plo
pathogen
wwwplospathogensorg
sign
leukemia
month
postinfect
onward
due
partial
protect
notabl
mice
except
mous
reveal
memori
cellular
tcell
respons
flow
cytometryand
vivo
ctl
assay
figur
ii
mice
sic
found
nonleukem
mice
thu
transient
treatment
shortli
infect
led
function
longlast
memori
ctl
respons
wherea
infectednon
treat
mice
develop
weak
primari
ctl
respons
consist
fact
individu
former
group
develop
leukemia
latter
group
understand
enhanc
cellular
immun
mount
infectedtr
mice
test
whether
ic
form
viral
antigen
passiv
immunotherapi
could
prime
antivir
ctl
respons
effici
frca
e
alon
aim
bone
marrowderiv
dendrit
cell
bmdc
puls
ic
made
frca
e
fric
frca
einfect
splenocyt
spfric
ii
noncomplex
frca
e
splenocyt
simpli
infect
frca
e
spfr
abil
stimul
prolifer
cfselabel
naiv
cell
transgen
mice
gagltcrtg
express
tcr
specif
b
restrict
gagl
assess
vitro
unloadedand
gaglload
bmdc
use
neg
posit
control
respect
gagltcrtg
tcell
prolifer
observ
presenc
either
frca
e
alon
frca
e
complex
fric
figur
surpris
gagl
deriv
gag
incorpor
virion
contrast
infect
splenocyt
spfr
infect
splenocyt
complex
mab
spfric
stimul
prolifer
figur
stronger
effect
spfric
show
cellular
ic
effici
simpli
infect
cell
stimul
prolifer
frca
e
infect
cellspecif
ctl
bmdc
figur
figur
next
address
whether
increas
cell
prolifer
depend
fccr
express
dc
turn
case
prolifer
gaglspecif
cell
decreas
experi
conduct
presenc
fccrblock
mab
mab
ii
cellular
ic
made
f
ab
fragment
spfrf
ab
instead
whole
mab
figur
importantli
extend
observ
vivo
situat
two
differ
amount
frca
e
infect
splenocyt
either
complex
spfric
respect
noncomplex
spfr
respect
administ
iv
mice
ctl
respons
analyz
day
later
ic
effici
stimul
prolifer
gaglspecif
cell
figur
figur
enhanc
ctl
respons
infect
cell
figur
figur
non
antibodycomplex
infect
splenocyt
regardless
amount
cell
use
result
indic
cellular
ic
enhanc
tcell
respons
vivo
antigen
form
ic
alreadi
report
effici
taken
dc
also
better
activ
cell
free
antigen
first
step
explain
stronger
antifrca
e
ctl
respons
present
figur
therefor
reason
dc
could
take
spfric
effici
spfr
would
lead
stronger
activ
uptak
dc
investig
follow
first
spfr
stain
membranelabel
dye
complex
given
dc
presenc
absenc
fccrblock
mab
variou
period
time
flow
cytometri
quantif
fluoresc
present
dc
data
figur
show
spfric
taken
faster
effici
spfr
differenti
uptak
effici
depend
fccr
data
consist
figur
show
fccrblock
mab
inhibit
gagltcrtg
tcell
prolifer
spfricactiv
bmdc
quantifi
abund
costimulatori
molecul
surfac
bmdc
cultur
presenc
spfr
spfric
marker
classic
use
monitor
dc
activ
slightli
reproduc
express
latter
case
figur
indic
better
activ
bmdc
spfric
signific
fraction
dc
express
retrovir
protein
mice
infect
mulv
also
consid
cellular
ic
may
favor
dc
dc
precursor
infect
frca
e
henc
led
gener
dc
alter
properti
possibl
influenc
ctl
respons
infect
treat
mice
first
step
ask
whether
uptak
spfr
complex
could
follow
product
infect
dc
achiev
assay
env
express
hour
give
spfr
spfric
bmdc
posit
control
spfr
spfric
given
infectionsensit
mu
dunni
fibroblast
parallel
experi
thirti
mu
dunni
cell
turn
posit
env
infect
presenc
spfr
spfric
respect
lower
infect
latter
case
consist
neutral
action
figur
contrast
bmdc
neg
whatev
condit
test
figur
surpris
bmdc
essenti
postmitot
cell
experiment
condit
use
mulv
requir
mitosi
provir
integr
subsequ
viral
function
express
prolifer
fccrexpress
precursor
dc
might
possibl
infect
vivo
lead
gener
dc
alter
properti
due
express
retrovir
protein
also
monitor
env
posit
splenic
dc
infectednontr
infectedtr
mice
postinfect
period
figur
splenic
dc
envposit
infectednontr
mice
day
postinfect
contrast
counterpart
posit
infectedtr
mice
time
point
envposit
cell
detect
later
time
day
thu
rather
section
two
group
dayold
mice
infect
frca
e
one
group
treat
infectedtr
hour
postinfect
day
postinfect
treat
infectednontr
group
mice
infect
treat
noninfectedtr
taken
neg
control
shown
data
present
repres
independ
experi
time
point
averag
valu
obtain
anim
per
time
point
except
case
day
anim
noninfectedtr
mice
neg
serum
viremia
sic
present
error
bar
indic
sem
total
antifrca
e
igg
c
assay
elisa
mice
infect
treat
b
one
independ
experi
similar
outcom
present
data
averag
valu
obtain
least
anim
per
time
point
noninfectedtr
mice
neg
antifrca
e
igg
therefor
present
error
bar
indic
sem
enhanc
number
dc
express
viral
env
vivo
treatment
diminish
presum
reduc
viral
spread
infectedtr
mice
limit
infect
dc
precursor
conclus
stronger
stimul
antifrca
e
ctl
respons
cellular
ic
correl
effici
uptak
dc
follow
effici
activ
unlik
involv
infect
dc
dc
precursor
enhanc
tcell
respons
infect
cell
endogen
antifrca
e
antibodi
gener
infectedtr
mice
infectedtr
mice
develop
longlast
tcell
respons
correl
high
titer
antifrca
e
antibodi
next
studi
whether
humor
respons
infectedtr
mice
could
contribut
longlast
mainten
ctl
group
day
postinfect
stain
mab
b
gagl
tetram
analyz
flow
cytometri
bd
phenotyp
character
primari
tcell
respons
infectedtr
anim
mice
infect
treat
figur
cell
isol
neg
select
spleen
infectedtreatedand
infectednontr
mice
day
postinfect
half
cell
stain
b
gagl
tetram
mab
analyz
flow
cytometri
parallel
half
cell
incub
pmaionomycin
plu
brefeldin
ifnc
product
tetram
cell
assess
intracellular
stain
statist
signific
data
infectedtreatedand
infectednontr
mice
establish
use
student
test
p
b
assay
gaglspecif
cell
infectedtr
infectednontr
mice
day
postinfect
cd
phenotyp
character
gaglspecif
cell
day
postinfect
data
agematch
noninfectednontr
naiv
mous
infectedtr
mice
present
stimul
prolifer
gagltcrtg
cell
sera
infectedtr
mice
bmdc
prepar
expos
variou
sourc
antigen
day
cocultur
csfelabel
cell
prepar
lymph
node
immun
via
mechan
similar
address
pool
sera
either
infectednontr
mice
pool
sacrif
day
postinfect
infectedtr
mice
pool
sacrif
day
use
form
ic
infect
splenocyt
tcell
prolifer
assay
describ
antifrca
e
antibodi
titer
higher
infect
treat
mice
vs
mgml
compar
tcell
prime
effici
serum
pool
ident
dilut
ident
antifrca
e
antibodi
concentr
gagltcrtg
cell
prolifer
detect
presenc
sera
infectedtr
mice
pool
presenc
sera
infectednontr
mice
pool
use
ident
dilut
figur
contrast
prolifer
seen
either
pool
sera
use
ident
antifrca
e
concentr
pool
versu
pool
figur
indic
endogen
antibodi
infectedtr
mice
promot
cell
prolifer
format
ic
frca
e
infect
cell
howev
effect
dosedepend
may
explain
tcell
respons
weaker
infectednontr
mice
infectedtr
one
former
display
lower
titer
antifrca
e
antibodi
result
suggest
enhanc
endogen
humor
respons
induc
infectedtr
mice
play
import
role
mainten
cellular
respons
administ
mab
disappear
antifrca
e
antibodi
endogen
gener
infectedtr
mice
show
cytolyt
activ
vivo
final
import
assess
whether
antifrca
e
antibodi
gener
endogen
infectedtr
mice
could
lyse
infect
cell
vivo
end
inject
iv
mixtur
noninfectedand
frca
e
infect
splenocyt
monthold
naiv
mice
follow
ip
administr
either
control
pb
ii
pool
sera
monthold
noninfectednontr
infectednontr
infectedtr
mice
case
ratio
two
cell
type
assay
flow
cytometri
circul
blood
cell
hour
later
addit
spontan
basal
cell
lysi
activ
observ
rapid
cytolyt
activ
frca
e
infect
cell
due
figur
experi
pool
sera
compar
volum
sera
inject
mice
cytolysi
assay
hour
later
figur
cytolysi
activ
sera
infectednontr
mice
compar
spontan
cytolysi
control
naiv
mice
wherea
sera
infectedtr
anim
much
stronger
thu
antifrca
e
antibodi
contain
sera
infect
treat
mice
lyse
frca
e
infect
cell
vivo
howev
vivo
cytolysi
infect
cell
observ
administr
higher
one
observ
sera
infectedtr
mice
probabl
due
fact
volum
pool
sera
use
contain
mg
antifrca
e
antibodi
mg
mab
administr
suggest
antivir
antibodi
concentr
might
critic
factor
induc
effici
cell
lyse
infect
cell
last
step
address
whether
antibodymedi
lysi
infect
cell
depend
nk
cell
andor
complement
aim
new
vivo
cytolysi
experi
conduct
either
deplet
nk
cell
administr
antiasialo
antibodi
inactiv
complement
activ
inject
cobra
venom
factor
increas
effici
assay
mixtur
noninfectedand
frca
e
infect
splenocyt
time
preincub
either
mab
antifrca
e
antibodi
infectedtr
mice
serum
prior
administr
latter
case
also
increas
quantiti
antifrca
e
antibodi
administr
mice
pool
sera
mice
high
serum
antivir
antibodi
concentr
nk
cell
deplet
result
dramat
decreas
infectedcel
lysi
antibodi
figur
sera
infect
treat
mice
figur
wherea
inactiv
complement
system
detect
effect
figur
point
role
adcc
infect
lysi
endogen
antivir
humor
respons
infectedtr
mice
data
point
immunomodulatori
effect
mab
permit
frca
e
infect
mice
mount
longlast
protect
immun
compris
strong
neutral
humor
respons
robust
ctl
contribut
subtli
interact
protect
individu
virallyinduc
diseas
longterm
vaccinelik
effect
last
long
termin
treatment
contrast
nonprotect
immun
respons
infectednontr
control
applic
persist
viral
infect
observ
import
therapeut
consequ
mabbas
immunotherapi
one
notabl
find
gener
effici
primari
ctl
respons
also
activ
longlast
antivir
memori
cell
involv
format
ic
antibodi
infect
cell
therefor
data
strongli
suggest
antibodi
target
protein
present
virion
also
surfac
infect
cell
crucial
advantag
effici
treatment
virallyinduc
diseas
context
passiv
immunotherapi
sever
nonexclus
mechan
may
explain
longterm
consequ
treatment
endogen
antivir
gagltcrtg
mice
transgen
tcr
recogn
b
restrict
gagl
peptid
prolifer
assess
day
later
flow
cytometri
control
experi
bmdc
cultiv
gagl
peptid
use
posit
control
frca
e
frca
e
ic
made
fric
cultur
medium
rpmi
serv
neg
control
b
stimul
cell
prime
frca
e
infect
splenocyt
presenc
absenc
noninfect
sp
infect
splenocyt
spfr
incub
presenc
concentr
spic
spfric
respect
typic
experi
independ
one
similar
outcom
present
statist
signific
spfr
spfric
group
experi
establish
use
student
test
p
see
figur
c
stimul
cell
prime
frca
e
infect
splenocyt
complex
either
f
ab
fragment
whole
mab
presenc
absenc
fccrblock
antibodi
frca
e
infect
splenocyt
spfr
complex
either
mg
f
ab
spfrf
ab
mg
mab
spfric
spfric
cocultur
bmdc
previous
incub
spfric
antifccr
fccrblock
antibodi
noninfect
splenocyt
incub
absenc
sp
presenc
mg
spic
use
control
stimul
cell
prime
frca
e
infect
splenocyt
presenc
sera
infectedtr
mice
infectednontr
mice
pool
correspond
sera
infectednontr
anim
sacrif
day
postinfect
wherea
pool
correspond
sera
infectedtr
mice
sacrif
day
pool
correspond
pool
antifrca
e
antibodi
concentr
adjust
pool
similar
result
obtain
independ
experi
individu
serum
sampl
mice
group
figur
vivo
enhanc
tcell
respons
frca
e
ic
spfr
spfric
administ
iv
noninfectednontr
mice
four
group
mice
n
use
two
inject
either
frca
e
infect
splenocyt
spfr
spfr
respect
absenc
two
inject
amount
frca
e
infect
splenocyt
complex
mg
spfric
spfr
respect
nine
day
later
test
expans
gaglspecif
cell
ctl
immun
firstli
data
show
strong
antivir
effect
mab
plasma
viremia
sic
adapt
immun
respons
could
emerg
suggest
immedi
effect
might
blunt
viral
propag
would
indirectli
provid
time
immun
system
mount
protect
antivir
immun
overwhelm
data
also
strongli
suggest
potent
effect
viral
load
due
neutral
activ
also
vivo
cytolyt
activ
frca
e
infect
cell
mainli
adccmedi
mechan
secondli
due
abil
enhanc
prime
cell
direct
frca
e
infect
cell
unlik
limit
viral
propag
sole
mechan
wherebi
mab
impact
endogen
humor
cellular
antifrca
e
respons
rather
direct
immunomodulatori
mechan
involv
format
ic
viral
particl
also
infect
cell
expos
env
surfac
seem
essenti
inde
igg
alreadi
shown
act
natur
adjuv
process
call
antibodi
feedback
regul
enhanc
immun
respons
antigen
specif
variou
set
includ
infect
pathogen
one
major
mechan
wherebi
administ
antibodi
oper
interact
ic
fccr
express
variou
immun
cell
type
includ
dc
interact
lead
enhanc
humor
stronger
tcell
respons
due
effici
dc
activationmatur
character
better
gener
present
antigen
peptid
howev
import
stress
potenti
therapeut
effect
icdc
interact
thu
far
princip
studi
context
antitumor
immunotherapi
use
vitro
techniqu
vivo
approach
mainli
reli
simplifi
ova
model
system
andor
graft
vitro
icload
dc
never
address
context
real
persistentleth
viral
infect
therefor
work
demonstr
first
time
cellular
ic
form
mabbas
passiv
immunotherapi
crucial
induc
long
last
protect
antivir
immun
also
show
interact
ic
fccr
express
dc
import
induct
enhanc
tcell
respons
support
idea
find
may
also
appli
infect
persist
virus
frca
e
enhanc
humor
respons
describ
upon
use
ic
therapeut
vaccinationbas
treatment
hbv
infect
ii
vitro
stimul
peripher
blood
mononuclear
cell
sivinfect
macaqu
ic
made
gag
gag
igg
led
effici
stimul
precursor
ctl
sivinfect
cell
stimul
gag
alon
howev
data
concern
protect
diseas
report
latter
studi
induc
longlast
protect
humoraland
cellular
antifrca
e
immun
igg
respons
significantli
differ
intens
antivir
activ
infect
treat
infectednontr
mice
figur
suggest
immunomodulatori
effect
affect
magnitud
qualiti
antifrca
e
humor
respons
importantli
enhanc
antibodi
respons
follow
short
passiv
immunotherapi
unlik
exclus
model
intens
treatment
juvenil
sivinfect
macaqu
antisiv
hyperimmun
serum
ig
acceler
appear
neutral
antibodi
correl
delay
onset
diseas
anim
ic
play
import
role
develop
antibodi
respons
via
differ
mode
action
work
need
address
ic
induc
enhanc
humor
immun
cellular
respons
like
scenario
enhanc
ctl
respons
infectedtr
mice
would
initi
target
frca
e
infect
cell
lyse
adcc
result
cellular
immun
complex
would
effici
taken
dc
owe
interact
fccr
effici
stimul
effector
cell
immun
system
sever
observ
support
scenario
uptak
frca
e
infect
cell
dc
increas
increas
inhibit
fccrspecif
antibodi
figur
ii
dc
effici
activ
spfric
spfr
least
assay
express
figur
iii
frca
einfect
splenocyt
effici
induc
antifrca
e
tcell
respons
nonmabcomplex
cell
vitro
figur
vivo
figur
iv
enhanc
tcell
respons
depend
ic
interact
fccr
express
dc
figur
one
challeng
elucid
intim
cellular
molecular
mechan
wherebi
cellular
icactiv
dc
induc
stronger
immun
respons
simpli
infect
cell
obviou
non
exclus
process
need
assess
includ
facilit
dc
migrat
lymphoid
organ
ii
increas
product
proinflammatori
cytokin
product
andor
decreas
product
immunosuppress
one
iii
better
process
cellular
antigen
andor
present
effector
cell
report
system
moreov
one
take
consider
vivo
cellular
icactiv
dc
may
interact
ctl
also
effector
cell
lymphocyt
whatev
mechan
involv
work
importantli
show
uptak
cellular
ic
allow
present
full
viral
antigen
repertoir
includ
determin
incorpor
virion
express
infect
cell
shown
presenc
cell
specif
gagl
epitop
gag
probabl
crucial
reject
infectedleukemogen
cell
ctl
suggest
effici
lysi
gaglload
splenocyt
administ
infectedtr
mice
figur
support
idea
coat
apoptot
tumor
cell
antibodi
enhanc
antitumor
immun
respons
variou
set
final
abl
target
infect
cell
vivo
plausibl
cell
lysi
adccmedi
mechan
may
creat
inflammatori
environ
favor
uptak
process
present
viral
antigen
determin
dc
cell
report
case
lytic
antitumor
mab
conclus
cell
ic
appear
twofold
effect
enhanc
quantit
qualit
viral
antigen
present
induc
potent
ctl
respons
direct
infect
cell
might
protect
antivir
immun
maintain
infectedtr
mice
disappear
data
strongli
suggest
longterm
protect
antivir
immun
infectedtr
mice
reli
complex
relationship
humor
cellular
antifrca
e
immun
follow
primari
respons
respect
first
question
humor
antifrca
e
respons
last
long
high
infectedtr
mice
compar
infectednontr
one
activ
vivo
describ
figur
noninfectednontr
mice
treatment
use
control
prolifer
gaglspecif
cell
statist
signific
group
establish
use
student
test
p
p
p
p
b
ctl
activ
gaglload
splenocyt
repres
mous
group
present
two
line
evid
argu
like
due
persist
stimul
residu
infect
cell
intens
posit
correl
number
cell
humor
respons
begin
decreas
moment
sic
becom
undetect
figur
ii
individu
anim
analysi
month
postinfectiontreat
unpublish
data
show
antifrca
e
antibodi
titer
higher
mice
residu
sic
compar
undetect
sic
viru
probabl
erad
latter
mice
second
import
issu
ctl
respons
maintain
low
level
infectedtr
anim
except
condit
challeng
endogen
antifrca
e
antibodi
lyse
frca
e
infect
cell
hypothes
establish
persist
infect
ctl
pool
weakli
longer
solicit
suggest
low
level
effectorlik
memorytcel
detect
unchalleng
infect
treat
mice
figur
would
avoid
exhaust
overstimul
consequ
preserv
possibl
strong
anamnest
respons
case
viru
reactiv
describ
variou
infect
system
support
idea
virusspecif
antibodi
alreadi
shown
essenti
longterm
mainten
memori
ctl
respons
upon
infect
mice
lymphocyt
choriomening
viru
lcmv
final
also
import
consid
humor
respons
might
facilit
activ
memori
ctl
case
viral
reactivationreinfect
mimick
challeng
infect
cell
show
antifrca
e
antibodi
format
ic
enhanc
prolifer
ctl
specif
infect
cell
figur
strengthen
idea
elicit
specif
ctl
respons
adequ
level
antibodi
direct
tumor
antigen
recent
report
therapeut
vaccin
experi
cancer
cell
thu
work
show
endogen
immun
respons
induc
immunotherapi
take
administ
mab
contain
viral
propag
long
end
treatment
also
suggest
antivir
immun
capabl
selfmainten
complex
balanc
humor
cellular
arm
immun
respons
critic
role
ic
avail
therapi
sever
chronic
viral
infect
base
use
pharmacolog
drug
andor
interferon
aim
inhibit
viral
spreadrepl
via
variou
mechan
enhanc
antivir
immun
respons
treat
patient
certain
case
even
lead
immun
amnesia
due
dramat
decreas
viral
antigen
report
case
hiv
therefor
therapeut
approach
clearli
depart
show
addit
direct
antivir
effect
passiv
immunotherapi
also
favor
mount
protect
antivir
immun
one
import
mechanist
explan
differ
immun
outcom
two
type
treatment
antivir
drug
enhanc
viral
antigen
present
apc
wherea
antivir
mab
opson
antigenbas
process
shown
consequ
work
identifi
thu
far
underappreci
immunomodulatori
properti
antivir
mab
underlin
possibl
major
differ
antivir
drug
experi
conduct
context
earli
postexposur
therapi
young
anim
stilldevelop
immun
system
moreov
neutral
mab
administ
rapidli
infect
therefor
possibl
applic
passiv
immunotherapystimul
antivir
immun
approach
may
limit
case
suspicion
infect
young
individu
lifethreaten
virus
hcv
hiv
import
challeng
determin
whether
passiv
mabbas
immunotherapi
also
influenc
immun
respons
chronic
infect
adult
mice
whatev
answer
question
fact
experi
conduct
young
anim
still
period
immun
system
matur
rais
possibl
possibl
first
applic
effect
might
treatment
mothertochild
transmiss
hiv
two
reason
need
novel
therapi
spontan
resist
certain
patient
current
chemotherapi
avail
neutral
mab
viru
see
introduct
first
month
maternallytransmit
neutral
antibodi
immunizedvaccin
mother
protect
babi
infant
variou
acut
infect
may
turn
incom
virus
effect
vaccin
process
call
natur
vaccin
howev
mother
hiv
carrier
usual
produc
neutral
antibodi
transmit
viru
babi
birth
natur
vaccin
take
place
import
question
would
therefor
whether
administr
exogen
antihiv
mab
perinat
infect
babi
could
reproduc
natur
vaccin
observ
case
viral
infect
fact
alreadi
cite
treatment
juvenil
sivinfect
macaqu
antisiv
hyperimmun
serum
ig
acceler
appear
neutral
antibodi
follow
delay
onset
diseas
certain
monkey
provid
support
idea
experiment
procedur
perform
studi
accord
local
anim
facil
cometh
institut
review
board
guidelin
approv
local
anim
facil
cometh
institut
review
board
supervis
french
lr
region
ceea
ethic
committe
anim
experiment
chairman
pr
michel
montpelli
frca
e
viral
stock
produc
describ
antimulv
env
mous
mab
purifi
previous
describ
f
ab
prepar
follow
concentr
mgml
mm
sodium
acet
ph
mix
pepsin
figur
influenc
frca
e
infect
cell
ic
bmdc
uptak
spfr
spfric
dc
spfr
spfric
given
bmdc
uptak
quantifi
flow
cytometri
presenc
absenc
fccrblock
mab
one
experi
similar
outcom
present
b
bmdc
activ
bmdc
incub
hour
presenc
spfr
spfric
lp
flow
cytometri
assay
one
repres
experi
independ
similar
outcom
present
c
assess
product
vitro
bmdc
infect
bmdc
cocultur
spfr
spfric
hour
flow
cytometri
assay
mhcii
env
cell
infectionsensit
mu
dunni
fibroblast
use
posit
control
parallel
experi
assay
envexpress
dc
vivo
mhcii
env
splenocyt
infectedtreatedand
infectednontr
mice
assay
flow
cytometri
day
postinfect
concentr
mgml
mm
sodium
acet
ph
mixtur
incub
hour
undigest
mab
remov
protein
column
chromatographi
unbound
fraction
collect
f
puriti
check
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
analysi
activ
f
shown
ident
intact
vitro
plaqu
reduct
neutral
assay
control
mab
sigma
fccrblock
mab
recogn
purchas
bioxcel
antiasialo
mab
use
nk
cell
deplet
wako
viral
titer
determin
use
focal
immunofluoresc
assay
fia
previous
describ
viru
neutral
activ
mous
sera
assay
previous
describ
figur
cytolyt
activ
frca
e
infect
cell
antifrca
e
antibodi
endogen
produc
infect
treat
mice
vivo
cytolysi
activ
assay
administr
cfselabel
frca
e
infect
splenocyt
spfr
follow
administr
antibodi
variou
sourc
cytometri
analysi
hour
cytolyt
activ
spfr
administ
iv
pb
ip
valu
averag
sem
experi
conduct
mice
per
condit
statist
signific
establish
use
student
test
p
b
cytolyt
activ
sera
infectedtreatedand
infectednontr
mice
administr
spfr
three
group
mice
treat
equival
volum
ml
pool
sera
noninfectednontr
infectednontreatedand
infectedtr
mice
valu
averag
sem
experi
conduct
mice
per
condit
statist
signific
sera
infectedtr
group
versu
two
group
determin
nonparametr
oneway
anova
test
dunn
multipl
comparison
posttest
c
cytolyt
activ
mice
treat
either
antink
antibodi
cobra
venom
factor
spfr
mix
pb
control
administ
iv
mice
treat
either
antink
antibodi
cobra
venom
factor
describ
method
section
valu
averag
sem
experi
conduct
mice
per
condit
statist
signific
data
obtain
sera
infectedtr
group
versu
obtain
two
group
establish
use
nonparametr
oneway
anova
test
dunn
multipl
comparison
posttest
cytolyt
activ
sera
infectedtr
mice
treat
antink
antibodi
cobra
venom
factor
spfr
mix
ml
pool
sera
infectedtr
administ
iv
mice
treat
either
antink
antibodi
cobra
venom
factor
describ
method
section
valu
averag
sem
experi
conduct
mice
per
condit
statist
signific
sera
infectedtr
group
versu
two
group
assess
due
reduc
number
mice
per
condit
briefli
frca
e
ffu
focusform
unit
dilut
ratio
serum
sampl
incub
hour
mix
use
infect
target
cell
overnight
cell
allow
reach
confluenc
time
ffu
score
fia
inbr
mice
b
haplotyp
use
studi
eight
dayold
mice
infect
ip
ml
viru
suspens
contain
ffuml
treat
mg
control
mab
one
hour
postinfect
day
postinfect
ip
administr
mice
examin
regular
interv
clinic
sign
erythroleukemia
spleen
swell
reduct
hematocrit
mice
sacrif
hematocrit
reach
avoid
unnecessari
pain
would
die
within
next
day
spleen
weight
either
death
day
sacrific
viremia
assay
sera
previous
describ
mab
serum
antifrca
e
antibodi
assay
describ
previous
mab
use
standard
quantif
antifrca
e
antibodi
respect
serial
dilut
singlecel
suspens
frca
e
infect
mous
spleen
prepar
ref
plate
confluent
indic
mu
dunni
cell
cultur
day
cocultur
ffu
score
fia
see
mice
inject
iv
frca
e
infect
splenocyt
resuspend
ml
pb
assay
cell
specif
frca
e
infect
cell
flow
cytometri
splenocyt
stain
becton
dickinson
pelabel
mhc
class
b
tetram
beckman
coulter
specif
friend
viru
gagl
peptid
b
gagl
tetram
min
room
temperatur
pba
pb
contain
fc
sodium
azid
cell
analyz
flow
cytometri
paraformaldehyd
fixat
altern
cell
isol
spleen
neg
select
kit
invitrogen
dynal
stain
b
gagl
tetram
becton
dickinson
mab
ebiosci
analyz
flow
cytometri
ifnc
product
cell
cultur
presenc
pmaionomycin
brefeldin
measur
use
intracellular
stain
kit
cytofixcytoperm
fixationpermeabil
becton
dickinson
accord
supplier
protocol
experi
conduct
describ
briefli
red
blood
cellfre
splenocyt
naiv
mice
either
puls
gagl
peptid
kept
unload
use
control
splenocyt
quantif
spontan
cell
death
adopt
transfer
experi
gaglloadedand
control
splenocyt
label
incub
either
mm
cfse
cfse
high
cell
mm
cfse
cfse
low
cell
contain
pb
respect
label
cell
mix
ratio
cell
mix
inject
iv
recipi
day
viral
challeng
hour
later
mice
sacrif
flow
cytometri
quantif
splenic
cfse
low
cfse
high
cell
ctl
activ
gaglload
splenocyt
calcul
ratio
cfse
high
cfse
low
cell
function
studi
perform
dc
obtain
bone
marrow
precursor
describ
ref
band
lymphocyt
macrophag
elimin
bone
marrow
cell
cultur
day
fcscontain
rpmi
medium
complement
gmcsf
uml
mm
glutamin
nonessenti
amino
acid
mm
bmercaptoethanol
mm
sodium
pyruv
presenc
co
time
use
immatur
dc
refer
bmdc
pure
assay
flow
cytometri
cell
doubli
posit
mhc
class
ii
bmdc
activ
assess
flow
cytometri
use
mab
direct
mhcii
ebiosci
becton
dickinson
h
stimul
spfr
spfric
lp
invivogen
mgml
retrovir
env
express
mhcii
bmdc
well
control
mu
dunni
cell
also
assay
flow
cytometri
use
fitclabel
mab
hour
cocultur
spfr
spfric
coexpress
env
mhcii
splenic
dc
assess
flow
cytometri
postinfect
prepar
splenocyt
sacrif
mice
ic
form
incub
frca
e
infect
splenocyt
spfr
either
mg
purifi
mab
spfric
ii
mg
f
ab
fragment
spfrf
ab
iii
sera
contain
antifrca
e
antibodi
spfrserum
nonimmun
sera
taken
control
latter
case
bmdc
cocultur
overnight
spfr
spfric
presenc
absenc
fccrblock
mab
spfrf
ab
spfrserum
wash
pb
dc
cultur
cell
purifi
lymph
node
gagltcrtg
transgen
mice
cell
express
gaglspecif
tcr
label
presenc
mm
cfse
cell
prolifer
follow
flow
cytometri
analysi
cfseand
cell
day
later
noninfect
splenocyt
use
control
experi
vivo
experi
frca
einfect
splenocyt
spfr
incub
mg
purifi
mab
administ
iv
naiv
mice
assess
gaglspecif
tcell
expans
potenti
cytotox
activ
describ
assay
use
deriv
ref
noninfect
frca
e
infect
splenocyt
label
mm
sp
cfse
low
mm
spfr
cfse
high
csfe
respect
mix
ratio
administ
iv
mice
afterward
receiv
either
mg
pool
sera
contain
antifrca
e
antibodi
ip
administr
altern
mixtur
noninfect
frca
e
infect
splenocyt
ratio
preincub
either
pool
sera
contain
antifrca
e
antibodi
infectedtr
mice
prior
iv
administr
ratio
cfse
low
cfse
high
cell
assay
flow
cytometri
hour
later
respect
assess
contribut
nk
cell
antibodymedi
cytolysi
ml
antiasialo
antink
antibodi
administr
iv
mice
day
prior
cytolysi
assay
assay
complement
unit
cobra
venom
factor
quiadel
administr
ip
day
prior
cytolysi
assay
unit
day
assay
respect
spfr
stain
redfluoresc
dye
sigma
concentr
mgml
min
half
prepar
use
form
spfric
fluoresc
spfr
spfric
place
presenc
dc
ratio
variou
period
time
either
measur
uptak
measur
simpl
bind
uptak
quantifi
flow
cytometri
subtract
simpl
bind
signal
data
present
mean
sem
statist
signific
group
determin
appli
either
student
test
two
group
compar
nonparametr
oneway
anova
test
dunn
multipl
comparison
posttest
three
group
compar
p
valu
lower
consid
statist
signific
figur
short
mab
treatment
prevent
mice
develop
leukemia
three
group
dayold
mice
infect
frca
e
one
group
treat
infect
treat
hour
postinfect
day
postinfect
second
group
treat
control
nonneutr
mab
isotyp
mab
sigma
infectedcontrol
mabtreat
third
group
treat
infectednontr
fourth
group
mice
infect
treat
taken
control
noninfectedtr
surviv
mice
b
hematocrit
present
data
averag
valu
obtain
least
anim
per
time
point
error
bar
indic
sem
line
indic
linear
regress
sake
clariti
percentag
hematocrit
infectedcontrol
mabtreat
mice
noninfect
treat
mice
shown
compar
infectednontr
infectedtr
respect
c
spleen
weight
infectedcontrol
mabtreatedand
infectednontr
mice
show
compar
spleen
swell
shown
bar
indic
mean
valu
data
present
compil
result
independ
experi
infectedtr
mice
n
infectednontr
n
mice
noninfectedtr
mice
n
infectedcontrol
mabtreat
n
mice
found
mb
tif
figur
character
humor
respons
develop
infectedtr
mice
complement
figur
antifrca
e
respons
antifrca
e
contain
sera
mice
analyz
figur
assay
elisa
one
independ
experi
similar
outcom
present
data
averag
valu
obtain
least
anim
per
time
point
noninfectedtr
mice
neg
antifrca
e
igg
present
error
bar
indic
sem
b
neutral
activ
mice
infect
describ
figur
figur
phenotyp
character
tcell
respons
infectedtr
anim
complement
figur
mice
infect
treat
figur
cell
isol
neg
select
spleen
agematch
noninfect
nontreat
mice
infectedtr
mice
day
postinfect
cell
stain
b
gagl
tetram
mab
flow
cytometri
analysi
data
agematch
noninfectednontr
mice
infectedtr
mice
present
data
togeth
result
present
figur
show
infectedtr
mice
gener
substanti
tcell
memori
pool
mainli
compos
effectormemori
cell
found
mb
tif
figur
statist
analysi
data
present
figur
prolifer
cfselabel
gagltcrtg
cell
measur
assay
quantifi
percentag
cell
decreas
cfse
fluoresc
cfse
stain
divid
two
cell
divis
data
independ
experi
statist
analyz
use
student
test
p
found
mb
tif
figur
complement
figur
vivo
enhanc
antifrca
e
tcell
respons
cellular
ic
spfr
spfric
administ
iv
noninfectednontr
mice
two
group
mice
n
use
one
frca
einfect
splenocyt
spfr
iv
inject
absenc
wherea
group
amount
frca
e
infect
splenocyt
use
immun
complex
format
mg
spfric
nine
day
later
expans
gaglspecif
cell
ctl
activ
assess
vivo
describ
figur
noninfectednontr
mice
treatment
nint
use
control
prolifer
gaglspecif
cell
data
obtain
mice
receiv
either
spfr
spfric
mous
present
togeth
control
mous
b
ctl
activ
gaglload
splenocyt
data
obtain
mice
receiv
either
spfr
spfric
present
togeth
control
mous
found
mb
tif
